{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:54:06Z","timestamp":1787961246296,"version":"build-2784847793"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Bevacizumab (Bev) is a humanized vascular endothelial growth factor monoclonal antibody that is used with chemotherapeutic drugs for the treatment of metastatic colorectal cancer (mCRC). Bev-induced hypertension (HT) is the most common adverse reaction during clinical practice. However, at present, appropriate antihypertensive agents for Bev-induced HT are unavailable. In this study, retrospective analysis of clinical data from mCRC patients who received renin-angiotensin system inhibitors (RASIs) showed significant survival benefits of overall survival (OS) and progression-free survival (PFS) over patients who received calcium channel blockers (CCBs) and patients who received no antihypertensive drug (NO: Y2020046 retrospectively registered). An experiment of HCT116 colon cancer cell xenografts in mice confirmed that combined treatment of Bev and lisinopril (Lis), a RASI, synergistically inhibited subcutaneous tumor growth and enhanced the concentration of 5-fluorouracil (5-Fu) in tumor tissues. Our results showed that the addition of Lis did not interfere with the vascular normalization effect promoted by Bev, but also inhibited collagen and hyaluronic acid (HA) deposition and significantly downregulated the expression of TGF-\u03b21 and downstream SMAD signaling components which were enhanced by Bev, ultimately remodeling primary extracellular matrix components. In conclusion, RASIs and Bev have synergistic effect in the treatment of colorectal cancer and RASIs might be an optimal choice for the treatment of Bev-induced HT.<\/jats:p>","DOI":"10.3389\/fonc.2022.829059","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T04:43:32Z","timestamp":1656650612000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab"],"prefix":"10.3389","volume":"12","author":[{"given":"Tianshu","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingshi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO Consensus Guidelines for the Management of Patients With Metastatic Colorectal Cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-017-1101-6","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Treatment of Colorectal Cancer","volume":"23","author":"Watanabe","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.6004\/jnccn.2017.0077","article-title":"Systemic Management of Colorectal Cancer","volume":"15","author":"Messersmith","year":"2017","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"B4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","article-title":"Bevacizumab-Induced Hypertension: Clinical Presentation and Molecular Understanding","volume":"182","author":"Li","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12344","article-title":"Angiogenesis Inhibitors in Cancer Therapy: Mechanistic Perspective on Classification and Treatment Rationales","volume":"170","author":"El-Kenawi","year":"2013","journal-title":"Br J Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1161754","article-title":"Novel Anti-Angiogenic Therapeutic Strategies in Colorectal Cancer","volume":"25","author":"Tampellini","year":"2016","journal-title":"Expert Opin Invest Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2165\/11590180-000000000-00000","article-title":"Bevacizumab-Induced Hypertension: Pathogenesis and Management","volume":"25","author":"Syrigos","year":"2011","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"B8","article-title":"Common Terminology Criteria for Adverse Events Version 5.0 Published November 27, 2017","year":"2017"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.10.003","article-title":"Treatment of Hypertension: The ESH\/ESC Guidelines Recommendations","volume":"128","author":"Cuspidi","year":"2018","journal-title":"Pharmacol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/HYP.0000000000000065","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertens (Dallas Tex 1979)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report","volume":"289","author":"Chobanian","year":"2003","journal-title":"Jama"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5603\/KP.2016.0156","article-title":"2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines","volume":"74","author":"Zamorano","year":"2016","journal-title":"Kardiol Polska"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/sux019","article-title":"ANMCO\/AIOM\/AICO Consensus Document on Clinical and Management Pathways of Cardio-Oncology: Executive Summary","volume":"19","author":"Tarantini","year":"2017","journal-title":"Eur Heart J Suppl"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2174\/157016112800812836","article-title":"Angiogenesis and Hypertension: The Dual Role of Anti-Hypertensive and Anti-Angiogenic Therapies","volume":"10","author":"Ferroni","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"360ra135","DOI":"10.1126\/scitranslmed.aaf5219","article-title":"Anti-VEGF Therapy Induces ECM Remodeling and Mechanical Barriers to Therapy in Colorectal Cancer Liver Metastases","volume":"8","author":"Rahbari","year":"2016","journal-title":"Sci Trans Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-011-1254-y","article-title":"Colorectal Cancer Desmoplastic Reaction Up-Regulates Collagen Synthesis and Restricts Cancer Cell Invasion","volume":"346","author":"Coulson-Thomas","year":"2011","journal-title":"Cell Tissue Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e11-06-0537","article-title":"Matrix Rigidity Regulates a Switch Between TGF-\u03b21-Induced Apoptosis and Epithelial-Mesenchymal Transition","volume":"23","author":"Leight","year":"2012","journal-title":"Mol Biol Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.584747","article-title":"Integrating Tumor Stroma Biomarkers With Clinical Indicators for Colon Cancer Survival Stratification","volume":"7","author":"Chen","year":"2020","journal-title":"Front Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2800","article-title":"Collagen Signaling Enhances Tumor Progression After Anti-VEGF Therapy in a Murine Model of Pancreatic Ductal Adenocarcinoma","volume":"74","author":"Aguilera","year":"2014","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular Mechanisms and Clinical Applications of Angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70212","article-title":"Recent Molecular Discoveries in Angiogenesis and Antiangiogenic Therapies in Cancer","volume":"123","author":"Welti","year":"2013","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.06.091","article-title":"Natural Products Against Renin-Angiotensin System for Antifibrosis Therapy","volume":"179","author":"Yang","year":"2019","journal-title":"Eur J Med Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-015-0617-1","article-title":"Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers Therapy and Colorectal Cancer: A Systematic Review and Meta-Analysis","volume":"26","author":"Dai","year":"2015","journal-title":"Cancer Causes Control CCC"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2015.630","article-title":"Angiotensin II Type-1 Receptor Blockers Enhance the Effects of Bevacizumab-Based Chemotherapy in Metastatic Colorectal Cancer Patients","volume":"3","author":"Osumi","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-019-03379-y","article-title":"Angiotensin I-Converting Enzyme Inhibitors\/Angiotensin II Receptor Blockers may Reduce Tumor Recurrence in Left-Sided and Early Colorectal Cancers","volume":"34","author":"Ozawa","year":"2019","journal-title":"Int J Colorectal Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118838","article-title":"Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats","volume":"98","author":"Volpert","year":"1996","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.toxlet.2018.05.036","article-title":"Perindopril, Fosinopril and Losartan Inhibited the Progression of Diethylnitrosamine-Induced Hepatocellular Carcinoma in Mice via the Inactivation of Nuclear Transcription Factor Kappa-B","volume":"295","author":"Saber","year":"2018","journal-title":"Toxicol Lett"},{"key":"B29","doi-asserted-by":"publisher","first-page":"k4209","DOI":"10.1136\/bmj.k4209","article-title":"Angiotensin Converting Enzyme Inhibitors and Risk of Lung Cancer: Population Based Cohort Study","volume":"363","author":"Hicks","year":"2018","journal-title":"BMJ (Clinical Res ed)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive Drugs and Risk of Cancer: Network Meta-Analyses and Trial Sequential Analyses of 324,168 Participants From Randomised Trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1868","article-title":"Bevacizumab has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells","volume":"17","author":"von Baumgarten","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.671.65.3","article-title":"Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination With Cytotoxic Therapy in Preclinical Studies","volume":"65","author":"Gerber","year":"2005","journal-title":"Cancer Res"},{"key":"B34","article-title":"Heterogeneity of Angiogenesis and Blood Vessel Maturation in Human Tumors: Implications for Antiangiogenic Tumor Therapies","volume":"60","author":"Eberhard","year":"2000","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e34861","DOI":"10.7554\/eLife.34861","article-title":"Capillary Pericytes Express \u03b1-Smooth Muscle Actin, Which Requires Prevention of Filamentous-Actin Depolymerization for Detection","volume":"7","author":"Alarcon-Martinez","year":"2018","journal-title":"Elife"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1159\/000087840","article-title":"Absence of Smooth Muscle Actin-Positive Pericyte Coverage of Tumor Vessels Correlates With Hematogenous Metastasis and Prognosis of Colorectal Cancer Patients","volume":"69","author":"Yonenaga","year":"2005","journal-title":"Oncology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1648","article-title":"VX680 Suppresses the Growth of HepG2 Cells and Enhances the Chemosensitivity to Cisplatin","volume":"7","author":"Yao","year":"2014","journal-title":"Oncol Lett"},{"key":"B38","article-title":"Addition in Drug Combination","volume":"1","author":"Jin","year":"1980","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22058","article-title":"VEGFA, FLT1, KDR and Colorectal Cancer: Assessment of Disease Risk, Tumor Molecular Phenotype, and Survival","author":"Slattery","year":"2014","journal-title":"Mol Carcinog"},{"key":"B40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Sci (New York NY)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2808-6","article-title":"Current Controversies in the Management of Metastatic Colorectal Cancer","volume":"76","author":"Vera","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jso.2930530111","article-title":"Immunohistologic Analysis of the Extracellular Matrix Components of the Fibrous Stroma of Human Colon Cancer","volume":"53","author":"Miura","year":"1993","journal-title":"J Surg Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(02)00037-X","article-title":"Expression of Hyaluronate and Hyaluronate Synthase in Human Primary Tumours and Their Metastases in Scid Mice","volume":"188","author":"Jojovic","year":"2002","journal-title":"Cancer Lett"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2004.05.018","article-title":"Hyaluronan Mediates Adhesion of Metastatic Colon Carcinoma Cells","volume":"122","author":"Laurich","year":"2004","journal-title":"J Surg Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2403","article-title":"VEGF-Targeted Therapy: Mechanisms of Anti-Tumour Activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.24.10145","article-title":"Antiangiogenic Agents and HIF-1 Inhibitors Meet at the Crossroads","volume":"8","author":"Rapisarda","year":"2009","journal-title":"Cell Cycle (Georgetown Tex)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: The Master Regulator of Fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cbi.2018.07.008","article-title":"New Insights Into TGF-\u03b2\/Smad Signaling in Tissue Fibrosis","volume":"292","author":"Hu","year":"2018","journal-title":"Chemico-biol Interact"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1318415110","article-title":"Combining Two Strategies to Improve Perfusion and Drug Delivery in Solid Tumors","volume":"110","author":"Stylianopoulosa","year":"2013","journal-title":"PNAS"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2020.10965","article-title":"SP1\/TGF\u2212\u03b21\/SMAD2 Pathway is Involved in Angiogenesis During Osteogenesis","volume":"21","author":"Ding","year":"2020","journal-title":"Mol Med Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2011.09.041","article-title":"TGF-Beta Signalling in Colon Carcinogenesis","volume":"314","author":"Lampropoulos","year":"2012","journal-title":"Cancer Lett"},{"key":"B52","article-title":"Circulating Transforming Growth Factor Beta 1 as a Predictor of Liver Metastasis After Resection in Colorectal Cancer","volume":"7","author":"Tsushima","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.23230","article-title":"The Role of TGF-Beta\/SMAD4 Signaling in Cancer","volume":"14","author":"Zhao","year":"2018","journal-title":"Int J Biol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1818357116","article-title":"Losartan Treatment Enhances Chemotherapy Efficacy and Reduces Ascites in Ovarian Cancer Models by Normalizing the Tumor Stroma","volume":"116","author":"Zhao","year":"2019","journal-title":"Proc Natl Acad Sci United States Am"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin Inhibition Enhances Drug Delivery and Potentiates Chemotherapy by Decompressing Tumour Blood Vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"478597","DOI":"10.1155\/2013\/478597","article-title":"Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials","volume":"2013","author":"Ong","year":"2013","journal-title":"ISRN Cardiol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i13.1394","article-title":"Mouse Models of Colorectal Cancer: Past, Present and Future Perspectives","volume":"26","author":"B\u00fcrtin","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3791\/484","article-title":"Orthotopic Mouse Model of Colorectal Cancer","author":"Tseng","year":"2007","journal-title":"J Vis Exp"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver Metastasis Restrains Immunotherapy Efficacy via Macrophage-Mediated T Cell Elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e2105323118","DOI":"10.1073\/pnas.2105323118","article-title":"Dendritic Cell Paucity in Mismatch Repair-Proficient Colorectal Cancer Liver Metastases Limits Immune Checkpoint Blockade Efficacy","volume":"118","author":"Ho","year":"2021","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.829059\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T04:43:36Z","timestamp":1656650616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.829059\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":60,"alternative-id":["10.3389\/fonc.2022.829059"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.829059","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"article-number":"829059"}}